Home

treatent

Schizophrenia

Read time: 4 min

Congress highlights

If one antipsychotic is good, why aren’t two better? Polypharmacy debated

Increased risk of side effects, reduced compliance, lack of rationale and, above all, no evidence...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind

You are leaving Progress in Mind

Continue to

Cancel

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Decline

Congress

Channels

Choose a channel

Go to Progress in Mind

treatent

If one antipsychotic is good, why aren’t two better? Polypharmacy debated

Channels

Choose a channel

Go to Progress in Mind

Select country

treatent

If one antipsychotic is good, why aren’t two better? Polypharmacy debated